ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026
[A single-center study on the clinical characteristics of 15 cases of large granular lymphocytic leukemia].
Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study retrospectively analyzed the clinical data of 15 patients diagnosed with large granular lymphocytic leukemia (LGLL) at the First Affiliated Hospital of Chongqing Medical University between January 2017 and December 2024. The median age was 50 years, and the main clinical manifestations included fatigue (73.3%), splenomegaly (46.7%), and lymphadenopathy (33.3%). None of the patients had autoimmune diseases. Laboratory examinations primarily demonstrated decreased hemoglobin levels (100%) and/or neutropenia (73.3%). The bone marrow smears showed an increase in lymphocyte proportion, and pure red cell aplasia was frequently observed. The typical immunophenotype was TCRαβ(+)TCRγδ(-)CD3(+)CD4(-)CD8(+)CD16(-)CD10(-)CD30(-)CD45RA(+)CD45RO(-)CD56(-)CD25(-), with monoclonal T-cell proliferation confirmed in all patients. Further, 8 patients demonstrated decreased complement C3 or C4 levels. The overall response rate of first-line immunosuppressive therapy for patients with LGLL was 85.7% (12/14) .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.